INTRODUCTION
Maintenance of genomic integrity is critical for the survival of an organism. The genetic information is protected by processes such as DNA repair, cell-cycle checkpoints, and apoptosis. DSBs are considered as one of the most lethal types of DNA damage within cells. Unrepaired DSBs can lead to chromosomal rearrangements such as translocations, deletions, etc., resulting in oncogenic transformations or cell death (Nambiar and Raghavan, 2011; Zhu et al., 2002) . In higher eukaryotes, NHEJ is one of the primary mechanisms of DSB repair and is active throughout the cell cycle (Mao et al., 2008) . During NHEJ, KU70/KU80 heterodimer binds to the DNA ends and recruits proteins such as DNA-PKcs, Artemis, or Pol m or l to the repair site, resulting in end-processing followed by Ligase IV, XRCC4, and XLF complex-mediated ligation (Gostissa et al., 2011; Lieber, 2010; Sharma and Raghavan, 2010) .
Besides Ligase IV, Ligase I and III are the other two ligases in mammals . Ligase IV has a multidomain architecture, consisting of a conserved ligase domain at N terminus and a tandem BRCT domain at the C terminus. The central catalytic domain comprises adenylation and oligo-binding domains. It has been shown that N-terminal DNA binding domain (DBD) of Ligase IV is crucial for its interaction with DNA (Jayaram et al., 2008) . However, unlike Ligase I, there is limited information about the structure of DBD of Ligase IV because it is yet to be crystallized (Pascal et al., 2004; Sibanda et al., 2001) .
Radio-and chemotherapy lead to the generation of DSBs as intermediates during their action. NHEJ plays a major role in providing resistance to cancer cells to these agents (Begg et al., 2011) . For example, KU70/KU80 is overexpressed in breast and gastric cancers (Pucci et al., 2001 ). Higher expression of DNA-PKcs has been correlated with radioresistance in oral squamous cell carcinoma, lung carcinoma, and esophageal cancer (Shintani et al., 2003; Sirzé n et al., 1999) . Further, chemoresistant murine breast cancer cells exhibit reduced levels of gH2AX foci upon g-radiation implying hyperactive DSB repair (Zhang et al., 2010) . Patients with mutations or lower levels of Ligase IV are shown to be radiosensitive (Riballo et al., 1999) . In addition, polymorphisms in XRCC4 and Ligase IV have been reported in breast cancers (Kuschel et al., 2002) . Thus, downregulation of NHEJ in cancer cells could lead to elevated sensitivity to radiation and chemotherapeutic agents. This prompted us to hypothesize that inhibition of NHEJ can be used as a means of making cancer cells hypersensitive to radiations and other DSB inducing agents. We chose Ligase IV as a potential target because it is the crucial enzyme involved in NHEJ. Specifically, we considered strategic targeting of the DBD of Ligase IV such that it reduces its binding affinity for DSBs and deters its physiological function.
In the present study, we identify SCR7 as a putative inhibitor of NHEJ. SCR7 blocked end-joining (EJ) by interfering with Ligase IV binding to DNA, thereby leading to accumulation of DSBs within the cells, culminating into cytotoxicity. Further, using various mouse models, we show that SCR7 impedes progression of tumor growth by activating intrinsic pathway of apoptosis and thereby enhancing lifespan. Finally, we demonstrate that treatment with SCR7 resulted in a significant increase in the sensitivity of tumors toward radiation and etoposide.
RESULTS

Structure of the Complex Containing DBD of Human Ligase IV Bound with DSBs
In absence of structural information for DBD of Ligase IV, a representative 3D model of human Ligase IV (1-241 aa) was built by a threading approach (I-TASSER) using multiple templates arising from crystal structures of DBDs of other Ligases. DBD of Ligase IV exhibited overall structural similarity with that of Ligase I (RMSD = 1.6 Å for 190 C a atoms) ( Figure 1A ). It is noted that the conserved RLRLG and ELGVGD motif of the DBD of Ligase I that interacts with nicked DNA (Pascal et al., 2004 ) is conserved spatially in DBD of Ligase IV (DLKLG and AYGIKE in Ligase IV), suggesting that these ligases might exhibit similar contacts with the substrate DNA ( Figure 1A ). Multiple sequence alignment of DBDs of other ligases also showed the conservation of this motif ( Figure S1A available online). Based on these clues, (E-G) Effect of SCR7 on EJ of 5 0 -5 0 noncompatible (E), 5 0 -3 0 noncompatible (F), and blunt (G) ends.
(H) Effect of Ligase I inhibitor, SCR5, on joining of 5 0 compatible ends.
(I) Agarose gel showing effect of SCR7 on plasmid based EJ. ''M'' is a 2 log DNA ladder. In (D-I), the bar diagram represents quantification of respective EJ products from a minimum of three independent experiments and represented as mean ± SEM. See also Figure S1 and Table S1 .
a DNA-containing DSB was docked with DBD of Ligase IV. Side chains of Lys30, Arg32, Lys35, Arg69, Lys195, Gly197 (main chain NH), Ser199, Gln201, Lys85, and Tyr82 from the DBD of Ligase IV were found to be involved in hydrogen bonding with anionic oxygen (Sp) of phosphates of DSB ( Figure 1B ).
Designing Potential Inhibitors of Ligase IV
A previous docking study on Ligase I with potential inhibitors had identified the small molecule L189 to possess inhibitory action against all three mammalian ligases (Chen et al., 2008) . Its docking with the current homology modeled complex of Ligase IV DBD and substrate DSB DNA duplex helped us in understanding possible interactions that could be exploited in designing potential Ligase IV inhibitors. Examining the amino acid composition of binding pocket together with multiple sequence alignment (Figure S1A) suggested that placing a substituent (ring C) emanating from amine group meta to the SH group (ring A) such as benzaldehyde might increase its inhibitory action. In silico docking of the modified compound indicated that addition of the ring C could result in the loss of vital interactions involving conserved basic residues viz., Lys35, Lys30 or Lys184, Arg188 of DBD of Ligase IV, and anionic phosphates of DNA duplex, in addition to other conserved residues ( Figure S1B ). The designed inhibitors were then docked with DBD of Ligase IV, and their binding energies estimated. The results pointed to a favorable binding energy (À29.14 kcal/mol) for the compound SCR7 as compared to others ( Figures 1C and S1C) . Further, the inhibitors were synthesized and characterized ( Figures 1C and S1D ).
SCR7 Inhibits End-Joining of Various DSBs
Previously, it was shown that testicular cell-free extracts are proficient in NHEJ (Sathees and Raman, 1999; Sharma et al., 2011) . Thus, a cell-free repair assay system derived from rat testes was used to study the effect of putative Ligase IV inhibitors on NHEJ (Figures S1E and S1F) (Kumar et al., 2010; Sharma et al., 2011) . The results showed inhibition of end-joining of DSBs (5 0 overhangs) by different compounds, and SCR7 was found to be the most potent ( Figures S1G and S1H ). The purity of SCR7 was characterized by MS and LC-MS. Previously reported ligase inhibitors, L189 (referred as SCR6) and L82 (inhibits Ligase I, SCR5), were used as controls (Chen et al., 2008 Figures 1D-1G ). However, when extracts from liver and kidney, possessing lower NHEJ were used, SCR7 inhibited the joining even at 10 mM ( Figures  S2A and S2B ). On the other hand, SCR5 did not inhibit EJ catalyzed by testicular extracts ( Figure 1H ). SCR7 could also inhibit EJ of a plasmid DNA linearized with EcoRI, HindIII (5 0 overhangs) or PstI (3 0 overhangs) ( Figure 1I ). Thus, SCR7 inhibited EJ irrespective of configuration of DSBs.
SCR7
Interferes with Ligase IV Activity and Inhibits NHEJ Ligase IV/XRCC4 complex can efficiently join compatible ends (Gu et al., 2007) , whereas joining of noncompatible termini requires additional proteins for end processing. To further confirm whether SCR7 interfered with Ligase IV activity, we used purified Ligase IV/XRCC4 complex for joining assay (Figures S2C, S2F, S2H, and 2A) . Results showed that incubation with increasing concentrations of SCR7 inhibited the formation of multimers at 200 mM and above, unlike SCR5 ( Figures 2B and 2C) .
The effect of SCR7 on joining catalyzed by T4 DNA ligase and mammalian Ligase I and III was investigated to test its specificity. In the case of T4 DNA ligase, no reduction in the joining was observed when compatible ends were used ( Figure 2C ). Further, SCR7 did not affect joining catalyzed by Ligase I on nicked substrates when equimolar concentration of protein was used ( Figures 2D and S2D and S2H ). However, when purified Ligase IIIa/XRCC1 was used, SCR7 inhibited the ligation of nicked substrates (Figures 2D and S2E, S2H, and S2I) . In order to further validate the specificity of SCR7 with respect to NHEJ in cell-free extracts, Ligase IV complementation was performed. Results showed that the addition of SCR7 to the testicular extracts abrogated end-joining ( Figure 2E , lane 3, and 2F). Interestingly, addition of purified Ligase IV/XRCC4 restored joining including that of noncompatible ends (Figures 2E and 2F) , establishing SCR7 as an inhibitor of NHEJ. Studies using Circular dichroism (CD) spectroscopy and gel shift assay ruled out the possibility of SCR7 acting as an intercalating agent ( Figures S3A-S3C ).
Binds to the DNA Binding Domain of Ligase IV and Interferes with Its Binding to DSBs Based on the above studies, we were interested in testing how SCR7 interferes with NHEJ. It is known that KU70/KU80 complex recruits and stabilizes Ligase IV/XRCC4 to the DNA ends (Nick McElhinny et al., 2000) . Results showed that Ligase IV/XRCC4 had more affinity to the KU70/KU80-coated ternary DNA complex, consistent with previous reports ( Figures 3A and 3B ) (Nick McElhinny et al., 2000) . Addition of purified Ligase IV/ XRCC4 to the KU:DNA complex resulted in a supershift due to its interaction with the KU bound DNA ( Figures 3B, 3C , and S3D). Interestingly, a dose-dependent reduction in supershift was observed, upon addition of SCR7 indicating the unavailability of Ligase IV to interact with DNA (Figures 3C, lanes 4-6, and S3D, lanes 3-9). More importantly, addition of Ligase IV/ XRCC4 (30, 60, and 90 fmol) to the reaction led to a concentration-dependent supershift, confirming the specificity of SCR7 to Ligase IV ( Figure 3C , lanes 7-9).
In order to exclude the effect of the interacting partner, XRCC4 and determine the domain responsible for binding of SCR7 to Ligase IV, we used purified Ligase IV and its DBD for CD spectroscopy ( Figures 3D, S2G , and S2H). Results showed a clear shift in the spectrum upon addition of SCR7 to Ligase IV or its DBD, as compared to control ( Figure 3D ). Further, the shift observed upon binding of SCR7 to DBD was directly proportional to its concentration until 6 3 10 À18 M and remained unchanged thereafter ( Figure S3E ). In addition, SCR7 binding also resulted in a significant decrease in the intrinsic fluorescence of DBD, suggesting the quenching of aromatic residues present at the interaction site ( Figure 3E ). Hence, these results suggest specific binding of SCR7 to DBD of Ligase IV. To examine the mechanism by which SCR7 disrupts binding of DBD of Ligase IV to the DNA duplex, we performed docking studies. A putative binding pocket defined by residues Arg69 and Asp193 to Gly197 (conserved DLKLG motif) within the DBD was chosen. Three poses for SCR7 were generated (data not shown), out of which a pose with favorable energy and appropriate shape complementarity was docked with DBD complexed with a DSB ( Figure 3F ). Atom groups OH, N, and SH from the ring A of SCR7 engage in a hydrogen bond with the side chain of Asp193, Arg69, and the backbone carbonyl of Leu196 ( Figure 3G ). As a result of the binding of SCR7, hydrogen bond interactions observed earlier, involving residues Arg69, Lys195, Gly197 (of the DLKLG motif), Ser199, and Gln201 of DBD and anionic oxygen of the phosphates of DNA duplex were completely lost ( Figures 3G and 3H) . Also, the aromatic ring C of SCR7 sterically blocked the interactions that could arise from the other highly conserved basic residues viz., Lys184 and Arg188 ( Figure 3F ). Loss of these critical interactions seemingly renders SCR7 as a competitive inhibitor, which is consistent with above observations (Figures 3, S3D , and S3E).
SCR7 Inhibits NHEJ within Cells and Leads to Generation of Unrepaired DSBs
An extrachromosomal assay system was used to evaluate the effect of SCR7 on NHEJ inside the cells. I-SceI-induced DSBs in pJS296 episome, which upon repair by NHEJ can restore In all panels quantification of EJ based on three independent experiments is represented as mean ± SEM. See also Figure S2 .
GFP expression ( Figure 4A ). Results showed GFP-positive recombinants upon expression of I-SceI confirming NHEJ (Figure 4A) . Interestingly, upon addition of SCR7, a decrease in the recombination, following normalization of transfection efficiency, was observed suggesting inhibition of NHEJ at the intracellular level ( Figure 4A ). Based on the above observations, we wondered whether the inhibition of innate NHEJ could result in the accumulation of Figure S3 . unrepaired DSBs at the genome level. To test this, we treated breast (MCF7) and cervical (HeLa) cancer cell lines with SCR7, followed by immunofluorescence and western blotting studies, by using anti-gH2AX. Results showed an increase in levels of gH2AX foci and protein, indicative of unrepaired DSBs within cells ( Figures 4B, 4C , and S4A-S4C). The number of foci observed due to SCR7 was comparable to those generated during siRNA knockdown of Ligase IV ( Figures 4B, 4C , and S4B). As a control, we used scrambled siRNA and siRNA against Ligase I and III ( Figures 4B, 4C , and S4B). However, similar In (A, C, D, H, I and J), the experiments shown were based on a minimum of three independent repeats and bar graph shows mean ± SEM (ns: not significant, *p < 0.05, **p < 0.01, ***p < 0.001). See also Figure S4 .
experiments on K562 cells did not yield any gH2AX foci, even at highest concentrations of SCR7, possibly due to low expression of Ligase IV ( Figure S4A ). To exclude the possibility that SCR7 could generate DSBs directly, independent of Ligase IV, N114 (Ligase IV À/À ), and Nalm6 (wild-type) cells were treated with SCR7 and assessed for gH2AX levels by western blotting and immunofluorescence ( Figures S4D and S4E) . Results showed that gH2AX expression remained unchanged upon SCR7 treatment in Ligase IV À/À cells, whereas a significant increase was noted in case of Nalm6 cells ( Figure S4D ). Both the cell lines showed substantial enhancement in gH2AX and foci expression upon bleomycin treatment, a known DSB inducing agent ( Figures S4D and S4E ). Overall, these results suggest that SCR7 does not induce DSBs directly to the genome and is Ligase IV dependent. Besides, upon incubation of oligomeric dsDNA or supercoiled plasmid DNA with increasing concentrations of SCR7, there was no evidence for DNA breaks ( Figure S4F ). Thus, SCR7 interferes with NHEJ in cells, leading to accumulation of unrepaired DSBs.
Cytotoxicity Induced by SCR7 Varies among Cancer Cells
To evaluate whether accumulation of DSBs leads to cell death upon SCR7 treatment, we performed a comparison of cytotoxicity among various human cell lines derived from breast (MCF7, T47D), cervical (HeLa), lung (A549), and ovarian (A2780) cancers; fibrosarcoma (HT1080); and leukemia (K562, Reh, Nalm6 and CEM), by using either MTT or trypan blue exclusion assays. Results showed a dose-dependent decrease in cell proliferation of MCF7, A549, and HeLa ( Figures 4D-4G ) with an IC 50 of 40, 34, and 44 mM, respectively, which was further confirmed by DIC imaging in MCF7 ( Figure 4E ). T47D, A2780, and HT1080 were also sensitive to SCR7, with an IC 50 of 8.5, 120, and 10 mM, respectively ( Figure 4G ). In contrast, SCR7-mediated cytotoxicity was limited when leukemic cell lines were used, except for Nalm6, which showed an IC 50 of 50 mM ( Figure 4G ). Expression of Ligase IV in different cancer cells could be correlated with their sensitivity to SCR7 ( Figure S4G) , with an exception of T47D, which has low levels of Ligase IV. This could be possibly due to a change in the proapoptotic to antiapoptotic ratio, because of its aberrant BCL2 status (Zapata et al., 1998) .
To delineate the effect of SCR7 on homologous recombination (HR) and NHEJ, an HR-deficient cell line, HCC1937 (BRCA1 À/À ) was used. Results showed elevated sensitivity of this cell line to SCR7, compared to its wild-type, MCF7, indicating that in the absence of HR, DSBs generated due to blockage of Ligase IV remain unrepaired leading to enhanced cell death ( Figure 4D ).
SCR7 Targets Ligase IV within the Cells to Induce Cytotoxicity
To further investigate whether the cytotoxicity observed was specific to Ligase IV inhibition, N114, and Nalm6 cells were treated with increasing concentrations of SCR7. Results showed that N114 remained unresponsive to SCR7, whereas Nalm6 exhibited a dose-dependent increase in cytotoxicity ( Figure 4H ). To confirm the observation, we knocked down Ligase IV by using antisense plasmid in Nalm6, MCF7 and HeLa cells. Treatment of these cells with SCR7 led to the loss of sensitivity, compared to sensitivity of mock transfected wild-type cells, establishing its specificity to Ligase IV ( Figures 4I, 4J, and S4H) . Similarly, overexpression of Ligase IV resulted in rescue of these cells from SCR7 ( Figures 4J and S4H, data not shown) . Besides, knockdown of Ligase III in Nalm6 did not result in significant loss of cytotoxicity, suggesting that SCR7 exerts its effects by targeting Ligase IV ( Figure 4I) .
It has been shown that blocking NHEJ can rescue interstrand crosslink (ICL) repair defects in Fanconi Anemia deficient cells (Adamo et al., 2010; Pace et al., 2010) . We reasoned that SCR7, being a NHEJ inhibitor, may suppress ICL sensitivity in FANCD2-deficient cells. To test this, we treated human PD20 (FANCD2 deficient) cells with mitomycin C (MMC) and SCR7. Results showed that treatment of MMC in PD20 resulted in elevated sensitivity ( Figure S4I ). Interestingly, addition of MMC along with SCR7 exhibited higher level of survival suggesting that SCR7 could block NHEJ in FANCD2-deficient cells (Figure S4I ). Elevated levels of chromosomal aberrations including deletions were also observed in HeLa cells upon treatment with SCR7 ( Figures S4J and S4K ).
SCR7 Prevents Progression of Tumor in Mice Resulting in Increased Life Span
To assess the effect of SCR7 on tumor progression, we tested different mice models. Results showed that SCR7 treatment (10 mg/kg, six doses) significantly reduced breast adenocarcinoma-induced tumor ( Figure 5A ). Untreated tumor animals survived only for 52 days, whereas treated animals exhibited $4-fold increase in lifespan ( Figure 5A ). We also tested the efficiency of SCR7 on Dalton's lymphoma mouse model (20 mg/kg, six doses) and found neither tumor regression nor increase in lifespan ( Figure 5B , data not shown).
Gross appearance of thigh tissues, liver, and spleen of control and treated animals on the 25 th and 45 th day after tumor development showed effect of SCR7 in a time-dependent manner ( Figure S5A ). Histopathological examination showed tumor cell proliferation in tumor controls, whereas a decrease was evident upon SCR7 treatment ( Figure 5C ). Morphology of hepatocytes in the treated group was comparable to that of normal animals (Figure 5C ). Administration of SCR7 did not show any significant difference in body weight ( Figure S5B ). Further, serum profile of normal animals treated with SCR7 (10 mg/kg) displayed no significant difference in the levels of alkaline phosphatase, alanine aminotransferase, creatinine, and urea ( Figure S5C ). Thus, treatment with SCR7 resulted in regression of tumors with no obvious adverse effects. In addition, HPLC analysis of serum following administration of SCR7 into mice (20 mg/kg) showed bioavailability of 114 mg/ml and a t 1/2 of 1 hr ( Figures  S6A and S6B) . Further, via noninvasive luciferase imaging, the effect of SCR7 (six doses, 20 mg/kg) on tumor progression of fibrosarcoma xenograft in real time was monitored for 2 weeks. Results showed decreased photon emission in the SCR7-treated group as compared to photon emission in the vehicle control (Figure 5D) . We also noted increased disease-free survival in the case of SCR7-treated mice (5/6 survived), as compared to that in untreated controls where only one animal survived until the 14 th day of treatment ( Figure 5D ). Antitumor activity of SCR7 was also evaluated in an ovarian cancer xenograft (six doses, 20 mg/kg) and a significant delay in tumor growth was observed ( Figure 5E ). Noticeably, at day 14 the tumor size was not reduced, despite a drastic reduction in the number of proliferating cells, suggesting that SCR7 could be a slower acting molecule for certain cancers ( Figure 5E ). Taken together, our results suggest that SCR7 can impede the tumor progression in different animal models of cancer.
Effect of SCR7 on B and T Cell Development
Ligase IV plays a key role in rejoining coding ends during V(D)J recombination through NHEJ, which raises the possibility that SCR7 treatment on mice may affect lymphocyte development. BALB/c mice administered with SCR7 (20 mg/kg, three doses) were examined by flow cytometry for CD3 + (T cell marker) cells in thymus, and CD19 + (B cell marker) cells in bone marrow ( Figures 5F and 5G ). An $25% reduction in T cell population was seen upon treatment with SCR7, whereas it was $40% in case of B cells ( Figures 5F and 5G) . Understandably, the absolute number of lymphocytes in spleen and bone marrow also showed significant difference between control and treated animals ( Figure 5H ).
In order to further assess the effect of SCR7 on V(D)J recombination, genomic DNA and RNA were extracted from the bone marrow of SCR7-treated mice. Results showed that treatment with SCR7 led to a reduction in the efficiency of recombination compared to that of controls, when genomic DNA was used for PCR amplification of one of the junctions ( Figure 5I ). Cloning and sequencing of the product confirmed its identity. Comparable results were obtained when thymic samples were used ( Figure 5I ). RT-PCR analysis also showed decreased levels of V H J558 recombination at the transcript level, further confirming the effect of SCR7 on V(D)J recombination in lymphoid cells (Figure 5J) . Importantly, defects in lymphocyte population (isolated from spleen or bone marrow) upon SCR7 treatment were transitory and restored following a recovery period of 18 days ( Figure 5H ).
SCR7 Significantly Enhances the Sensitivity of Cancer Cells to Radio-and Chemotherapeutic Agents
Because the effect of SCR7 was limited on tumors derived from Dalton's lymphoma (DLA) cells, we wondered whether combining SCR7, along with existing treatment modalities that induce DNA strand breaks, could enhance its sensitivity. To test this, we irradiated mice bearing tumors either (2 Gy, two doses) alone or in conjunction with SCR7 (20 mg/kg), whereas untreated and SCR7-treated mice served as controls. A reduction in tumor growth was noted upon treatment with radiation alone, whereas in conjunction with SCR7, it resulted in a significant decrease in tumor growth both after 7 and 14 days of treatment ( Figure 6A ). Further, we tested the effect of the chemotherapeutic drugs etoposide and 3-ABA (PARP inhibitor) on DLA in the presence of SCR7. Interestingly, a substantial reduction in tumor growth was seen when both SCR7 and etoposide were used together, as opposed to either used alone ( Figure 6B ). In contrast, the combination of PARP inhibitor and SCR7 did not yield any appreciable effect on tumor progression, perhaps due to its inability to generate DSBs ( Figure 6C ). 3-ABA induced cytotoxicity in the BRCA1 À/À cell line, HCC1937, served as the control for its bioactivity ( Figure S6C ). These results indicate that SCR7 potentiates the cytotoxic effects of irradiation and etoposide on tumor models in mice.
Based on the above study, we wondered whether SCR7 treatment along with bleomycin could enhance the frequency of DSBs in cancer cell lines. Results showed a higher number of gH2AX foci per cell upon addition of increasing concentrations of SCR7 in both MCF7 and HeLa cells, as compared to bleomycin alone (Figures 6D and 6E) . Overall, these results demonstrate that SCR7 in combination with additional therapeutic approaches like radiation or DSB inducing drugs can be used as a more effective strategy for treatment of cancers.
SCR7 Activates Intrinsic Pathway of Apoptosis to Induce Cytotoxicity
The observed tumor regression in mice and increased cell death in cancer cell lines by SCR7 prompted us to examine the underlying mechanism. Immunohistochemistry (IHC) studies showed that Ki67 (a cell proliferation marker)-positive tumor cells were substantially fewer in mice treated with SCR7 (10 mg/kg) ( Figure 7A ). pATM was detected only in SCR7-treated tumor sections, whereas basal level of ATM was observed both in tumor and treated sections ( Figure 7A ). Expression of p21 (cellcycle regulator) and apoptotic markers such as BID and Caspase 3 were also higher in treated tissues ( Figure 7A ). At the 25 th day of SCR7 treatment (10 mg/kg), tumor tissues exhibited TUNEL staining in the infiltrated tumor cells, in contrast to untreated tumor tissues ( Figure 7B ) indicating DNA fragmentation, which is a hallmark of apoptosis.
To further investigate the downstream signaling events associated with activation of apoptosis, we performed immunoblotting by using cell extracts prepared from SCR7 (20, 40 mM)-treated MCF7 cells. Results showed an increase in phosphorylation of ATM and activation of p53 ( Figure 7C) . A concomitant decrease in MDM2 was also noted, resulting in activation of proapoptotic proteins, PUMA and BAX ( Figure 7C ). Expression of BCL2 decreased, whereas the levels of proapoptotic protein, BAD, remained unchanged ( Figure 7C ). In addition, shorter fragments of MCL1, which acts as proapoptotic protein, were upregulated in a dose-dependent manner ( Figure 7C) . A dosedependent increase in PARP1, Caspase 3, and Caspase 9 cleavage was also seen ( Figure 7C ). Comparable results were also obtained when Ehrlich ascites breast adenocarcinoma (EAC), A549, and HeLa were used (Figures S7A-S7C ). However, K562 cells, which showed the least sensitivity to SCR7, did not show any evidence for activation of apoptosis ( Figure S7D) . Thus, the above results suggest that accumulation of DSBs upon SCR7 treatment activates p53-mediated intrinsic pathway of apoptosis.
DISCUSSION
Inhibition of NHEJ by SCR7 Leads to Accumulation of DSBs and Cytotoxicity in Cancer Cells
Various attempts have been made to design inhibitors against the proteins involved in DSB repair and DNA damage responses.
However, little is known about inhibitors against core NHEJ proteins, such as KU70/80 complex, Artemis, Ligase IV/XRCC4, Pol m, and Pol l. In the present study, we report an inhibitor of NHEJ, which manifests its action by disrupting sealing of DSBs, leading to accumulation of unrepaired breaks in the genome. This results in activation of ATM, which phosphorylates p53 and downregulates MDM2, culminating in activation of an intrinsic pathway of apoptosis (Banin et al., 1998) . Further, the imbalance in the pro/antiapoptotic ratio within the cells leads to activation of caspases, which results in PARP1 cleavage, DNA fragmentation, and, eventually, cell death ( Figure 7D ).
Recent studies have suggested that Ligase IIIa/XRCC1 may play a vital role in alternative-NHEJ (A-NHEJ), although its efficiency and regulation inside cells still remains unclear (Sallmyr et al., 2008) . It is also known that the level of A-NHEJ increases when either KU70/KU80 or Ligase IV/XRCC4 is inoperative (Simsek and Jasin, 2010). Because we noted that SCR7 can also inhibit ligation of nicks by Ligase IIIa/XRCC1, one would expect some effect on A-NHEJ. Although knockdown of ligase IV desensitized the cells toward SCR7, knockdown of Ligase III did not show a similar effect, suggesting that effect of SCR7 was majorly restricted to the former. Because Ligase IIIa/XRCC1 is also involved in base excision repair, it needs to be verified whether SCR7 has any effect on this pathway. Consistent with this, the Ligase IV knockout cell line did not exhibit cytotoxicity upon addition of SCR7. Further, overexpression of Ligase IV in sensitive cells resulted in a loss of SCR7 effect, confirming Ligase IV as the target of SCR7 within cells. The observed elevation in the survival of FANCD2-defective cells further validated such a conclusion.
Inhibition of NHEJ as a Tool for Cancer Therapeutics
Among the four tumor models explored for the therapeutic potential of SCR7, three were responsive. Interestingly, in one of the models, a 4-fold increase in the lifespan was observed and compared to controls. Morphological and histochemical analysis in conjunction with liver and kidney function tests suggested that SCR7 treatment did not result in any adverse effects. Being an inhibitor of one of the major DSB repair pathways, SCR7 may not necessarily provide selective obliteration of cancer cells. However, the faster proliferating nature of cancer cells could be exploited particularly when administered to the target cells. Cancer cells accumulate and tend to have more innate DNA damage due to higher rates of replication. It is also known that most cancer cells are defective in cell-cycle checkpoints and have shorter repair times (Begg et al., 2011) . Owing to these facts, cancer cells can be more sensitive to SCR7 as compared to surrounding normal tissues. This effect can be further enhanced when repair inhibitors such as SCR7 are utilized in conjunction with radio-or chemotherapy. Differential protection of normal tissues could also be achieved by preferential uptake of drug in tumor cells due to extensive vascularization.
It has been shown that inactivation of Ligase IV in mice leads to blockage of lymphopoiesis and V(D)J recombination Gao et al., 1998) . Apart from lymphocyte developmental defects, inactivation of Ligase IV in mice leads to late embryonic lethality primarily due to massive apoptosis in neuronal cells Gao et al., 1998) . It has also been shown that Ligase IV deficiency leads to chromosomal instability even in absence of DNA damaging agents and can lead to neoplastic transformations Frank et al., 1998; Gao et al., 1998) . However, such side effects were not observed in mice treated with SCR7. This could be attributed to lower concentrations, the number of doses, and the differential distribution of SCR7 in mice, in which genomic copy of Ligase IV is intact, in contrast to knockout mice. It appears that the stage at which the inhibitor is administered could also play a key factor because we do not observe any developmental defects associated with blockage of Ligase IV in 3-to 4-weekold mice.
SCR7 had an effect on V(D)J recombination in developing B and T cells, most likely due to a block in NHEJ, thus leading to a significant reduction in overall lymphocyte population. Interestingly, SCR7 did not lead to any permanent damage to the immune system because completion of treatment regime led to a restoration of the lymphocyte population. This was also evident from the observed increase in the life span of SCR7-treated mice with tumors. Noninvasive in vivo imaging of SCR7-treated or untreated mice bearing different human tumor xenografts also supports the idea that SCR7 does not interfere with other physiological processes in mice.
Accumulation of unrepaired breaks along with modalities that induce DSBs can be used as a strategy to further sensitize cancer cells to treatment. Our results showed that when treated along with SCR7, ionizing radiation (IR) and etoposide could enhance tumor regression more efficiently. The observed slower effect of SCR7 on A2780 tumor xenografts, further supports such a conclusion. This strategy can be of immense importance, particularly in case of resistant or unresponsive tumors, which are known to have hyperactive DNA repair mechanism.
In conclusion, we show that inhibition of Ligase IV results in the accumulation of DNA double-strand breaks, resulting in the activation of apoptosis in cancer cells. The strategy employed herein can be used for rational design of other inhibitors of Ligase IV and other proteins associated with NHEJ. Based on the choice of DSB repair pathway in a particular type of cancer, a targetbased therapy could be developed. Furthermore, the use of DNA repair inhibitors along with existing chemo-and radiotherapeutics could improve efficacy of treatment many fold.
EXPERIMENTAL PROCEDURES
Purification of Ligases
Ligase I, Ligase IIIa/XRCC1, Ligase IV/XRCC4, and DBD of Ligase IV were overexpressed in Escherichia coli and purified. See Extended Experimental Procedures for details.
NHEJ Assay
NHEJ assay was performed as described with modifications (Kumar et al., 2010; Sathees and Raman, 1999; Sharma et al., 2011) (Figures S1E and  S1F ). Cell-free extracts (0.5 mg) from testis or purified Ligase IV/XRCC4 (60 fmol) was preincubated with appropriate concentrations of Ligase inhibitors in NHEJ buffer (25 mM Tris-HCl, [pH 7.5], 75 mM NaCl, 10 mM MgCl 2 , 42.5 mM KCl, 0.025% Triton X-100, 100 mg/ml BSA, 10% PEG, and 5% glycerol) in a reaction volume of 10 ml at 25 C for 30 min. In case of reaction with noncompatible ends, buffer was supplemented with deoxyribonucleotide triphosphate (dNTPs). Because the compounds were dissolved in DMSO, a corresponding concentration of DMSO was used in control reactions. After preincubation with the inhibitors, [g-32 P]ATP end-labeled oligomeric DNA substrate (75 bp) possessing different termini (4 nM) was added to the mix and incubated for 2 hr at 25 C. Reactions were terminated by addition of EDTA (10 mM) and products were purified by phenol-chloroform extraction followed by precipitation. The reaction products were then resolved on 8% denaturing PAGE. The gel was dried and exposed and the signal was detected with a PhosphorImager (FLA9000, Fuji, Japan) and analyzed with Multi Gauge (V3.0) software. For quantification of NHEJ products, the area corresponding to the band of interest was selected in each lane, and the same size was selected in an area with no band from each lane of the gel for subtracting background. Intensity measured from each lane was indicated as photostimulated luminescence (PSL) units and plotted.
Joining Assay with the Nicked Substrates Nicked substrates were generated by annealing radioactively labeled MS68, MS69, and MS70 and incubated with equimolar concentrations of Ligase I (60 fmol) or Ligase IIIa/XRCC1 (60 fmol) for 1 hr at 25 C. Joined products were deproteinized and resolved on a 10% denaturing PAGE.
Complementation of SCR7 Inhibition with Purified Ligase IV Inhibition of end-joining reaction was carried out as described above by incubating testicular extracts with SCR7 (150 mM). Complementation experiment was carried out by adding increasing concentrations of purified Ligase IV/ XRCC4 complex (30, 60, and 120 fmol) along with the oligomeric DNA substrates (5 0 compatible and 5 0 -5 0 noncompatible ends) to the SCR7-treated extracts. Reactions were incubated for 2 hr at 25 C; products were purified and resolved on PAGE as described above.
Gel Mobility Shift Assay
For the binding studies, oligomeric DNA was incubated with KU or Ligase IV/ XRCC4 complex, and products were analyzed. See Extended Experimental Procedures for details.
Modeling and Docking Studies
The 3D structure of SCR7 was built and energy minimized with Discovery studio package (Discovery Studio 2.5. Accelrys, USA). Homolog model for the DBD of Ligase IV was built with I-TASSER. See Extended Experimental Procedures for details.
Intracellular NHEJ Assay
Intracellular NHEJ assay was performed as described earlier with modifications (Bennardo et al., 2008) . HeLa cells (3 3 10 5 ) were seeded in 6-well plates.
Ten micrograms of NHEJ plasmid substrate pJS296 alone or with I-SceI expression vector (20 mg) were transfected in absence or presence of increasing concentrations of SCR7 (5 and 20 mM) with lipofectamine 2000 (Invitrogen) as per manufacturer's recommendation. Equal concentration of DMSO served as the vehicle control. pcDNA 3.1-RFP plasmid was transfected in each case to determine the transfection efficiency.
Knockdown and Overexpression of Ligase IV Ligase IV knockdown was performed with siRNA or antisense Ligase IV plasmid by transfecting into MCF7, HeLa, and Nalm6 cells with oligofectamine and lipofectamine (Invitrogen), respectively, whereas overexpression was performed as per standard protocol. See Extended Experimental Procedures for details.
Determination of Effect of SCR7 in Combination with Radiation, Etoposide, and 3-ABA BALB/c mice were injected with DLA cells (0.25 3 10 6 ) intraperitoneally for tumor development, after which two batches of animals were divided into eight subgroups. Treatment was started after 5 days of DLA injection (d 0). Group I served as tumor control (n = 10). Group II (IR, n = 5) and III (IR + SCR7, n = 5) received two doses of radiation (2 Gy) on day 0 and 4. Besides radiation, Group III also received six doses of SCR7 (20 mg/kg) on alternate days from day 0. Group IV (etoposide, n = 5) and V (etoposide + SCR7, n = 5) received three doses of etoposide (10 mg/kg) intraperitoneally on day 0, 4, and 8. In addition to etoposide, Group V animals also received six doses of SCR7 (20 mg/kg) on alternate days from day 0. Group VI (3-ABA, n = 5) and VII (3-ABA+SCR7, n = 5) received three doses of 3-Aminobenzamide (10 mg/kg) on days 0, 4, and 8. Group VII received six doses of SCR7, as specified above. Group VIII (SCR7, n = 5) received six doses of SCR7 alone (20 mg/kg) on alternate days (0, 2, 4, 6, 8, and 10) and served as the control. Progression of tumor was monitored and data are presented as a bar diagram. Error bars and levels of significance are indicated in respective figure legends.
Flow Cytometric Analysis of Mice Lymphocytes BALB/c mice were injected with SCR7 and bone marrow, spleen, and thymus were collected, stained for appropriate markers, and used for flow cytometry.
For details see Extended Experimental Procedures. 
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